Radboud University Medical Center: Diabetes Mellitus, Type 2 trials

The registry lists 19 Diabetes Mellitus, Type 2 studies with Radboud University Medical Center as lead sponsor. 3 are open to participants now and 0 have results posted.

Phase 1 2Phase 2 5Phase 3 1Phase 4 2No phase 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• RAPIDE: The Feasibility of a Hybrid Care ModelNot yet recruitingNCT06735404Not applicable
• The GATE Study: Endoscopic Sutured Gastroplasty in Type 2 Diabetic, Obese Patients Using the Endomina DeviceNot yet recruitingNCT05599477Phase 2
• Visualizing Beta Cells After Bariatric SurgeryRecruitingNCT02542059
• The GATE Trial: Endoscopic Sutured Gastroplasty in Type 2 Diabetic, Obese Patients Using the Endomina DeviceStatus unknownNCT05711043Not applicable
• Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 DiabetesStatus unknownNCT04733508Not applicable
• Consequences of Hypoglycaemia on Cardiovascular and Inflammatory ResponsesCompletedNCT03976271Not applicable
• Imaging Pituitary ActiVation by ExendinCompletedNCT03923114Not applicable
• GLP1-imaging Before and After Bariatric SurgeryStatus unknownNCT03182231Phase 1/2
• Effect of Gelofusine on GLP1-receptor ImagingCompletedNCT02541734Phase 1/2
• Adipose Tissue Imaging in Type 2 DiabetesCompletedNCT02528695Not applicable
• ET-blockade and Exercise-induced Vascular Adaptations in T2DMCompletedNCT01779609Phase 4
• ET-blockade and Exercise Induced Blood Flow in T2DMCompletedNCT01779596Phase 4
• Liraglutide and Insulin Therapy in Patients With Type 2 DiabetesStatus unknownNCT01392898Not applicable
• The Effect of Anakinra on Insulin SecretionStatus unknownNCT01285232Not applicable
• Vildagliptin and Endothelium-dependent VasodilatationCompletedNCT01000688Phase 3
• Interleukin-1 Receptor Antagonist and Insulin SensitivityStatus unknownNCT00928876Phase 2
• Determinants of Insulin-induced Weight Gain in Type 2 Diabetes MellitusStatus unknownNCT00781495
• Effects of Atazanavir Treatment on Type 2 Diabetes Mellitus Related Endothelial DysfunctionCompletedNCT00696722Phase 2
• Effectiveness and Cost-effectiveness of the Diabetes Integrated Care Breakthrough CollaborativeCompletedNCT00160017